Volume 5, Number 10, Supplement 15 (October 2008)

Current Clinical Trials

1

AMG 479 in combination with exemestane or fulvestrant in postmenopausal women with locally advanced or metastatic breast cancer

Peter A. Kaufman, MD

Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH

Although conventional hormonal therapy is effective for patients with estrogen receptor-positive metastatic breast cancer, virtually all patients with metastatic disease will eventually become resistant to conventional hormonal agents and develop progressive disease. Available second- and third-line therapies are less than ideal, producing only modest therapeutic gains. This phase II study of AMG 479 in combination with exemestane or fulvestrant is currently enrolling postmenopausal women with hormone receptor-positive, locally advanced or metastatic breast cancer whose disease has progressed on conventional hormonal therapy. AMG 479, a targeted agent in early-stage clinical development at Amgen with an overall favorable side-effect profile, inhibits the type 1 insulin-like growth factor-receptor (IGF-1R) pathway involved in tumor-cell proliferation and growth. The study will determine whether AMG 479 can sensitize tumor cells to respond to second-line hormonal therapy.

abstract

full text

324 kb

© 2008 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

The opinions expressed herein are those of the authors or advertisers. The authors, editors, and publishers make every effort to ensure that no inaccurate or misleading data, opinion, or statement is published in this journal and that drug names, dosages, and recommendations are accurate. However, readers should confirm all dosage schedules against the manufacturer’s package information data. The Publisher, Editorial Board, and their employees accept no liability whatsoever for the consequences of any inaccurate or misleading data, opinion, or statement.